Bedside blood test may reveal how well heart failure treatment works

NCT ID NCT07762521

Not yet recruiting Knowledge-focused Sponsor: Mao Chen Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This observational study looks at whether changes in a blood marker called NT-proBNP, measured at the bedside, can reflect how well fluid is being removed in patients hospitalized with acute decompensated heart failure. Participants receive standard care, and researchers track NT-proBNP levels and congestion signs during the first days in the hospital. The goal is to see if this marker could serve as a useful indicator of treatment response, potentially guiding more personalized heart failure management in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Serial NT-proBNP measurement (a blood test measuring a heart stress marker)
What this could lead to
If successful, this could show that simple bedside NT-proBNP tests help doctors gauge how well heart failure treatment is working, potentially guiding more personalized care in the future.
What could go wrong
This is a small observational study, so it cannot prove cause and effect. The results may not apply to all heart failure patients, and the test is not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE (ADHF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.